A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients with Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

About this Study

The purpose of this study is to determine if GFB-887 is a safe and effective treatment for people with high levels of protein in their urine due to Diabetic Nephropathy (DN), Focal Segmental Glomerulosclerosis (FSGS), and Treatment-Resistant Minimal Change Disease (TR-MCD).  GFB-887 is an experimental drug that is not approved by the FDA for the treatment of DN, FSGS, or TR-MCD. 

Sponsor Protocol ID:GFB-887-201
IRB Number:2021-1120
Actively Enrolling
Interventional
Phase 2
March 07, 2022
Eligibility Criteria
18 years old
75 years old
Both Male and Female
No
No
No

Inclusion Criteria
Inclusion for Diabetic Nephropathy (DN) patients
  • Male of female 18-75 years of age
  • Diagnosis of type 2 diabetes with HbA1c less than or equal to 11 at screening
  • Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 at Screening
  • Currently receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for at least the last 3 months prior to screening
  • All females of that can be become pregnant and all males must agree to use contraception while on study drug and for at least 90 days after the final follow-up visit
Inclusion for Focal Segmental Glomerulosclerosis (FSGS) /Treatment-Resistant Minimal Change Disease (TR-MCD)
  • Male of female 18-75 years of age
  • diagnosis of FSGS or TR-MCD , based on either biopsy or FSGS based on genetic testing
  • eGFR greater than or equal to 30 mL/min/1.73 m2 at screening
  • Currently receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for at least the last 3 months prior to screening

Exclusion CriteriaExclusion for diabetic nephropahy (DN) patients
  • uncontrolled blood pressure, greater than 160/90
  • renal disease that requires immunosuppressive therapy
  • Positive HIV test or test indicating current hepatitis B or C infection at screening
  • Pregnant or breastfeeding
  • Body Mass Index (BMI) greater than 45
  • History of cancer, unless in disease free for at least 5 years
  • History of alcoholism or drug/chemical abuse within 12 months prior to screening
Inclusion for FSGS/TR-MCD patients
  • uncontrolled blood pressure, greater than 160/90
  • Currently on calcineurin inhibitor (CNI)
  • History of resistance to CNIs 
  • Received rituximab or cyclophosphamide within the last 120 days prior to screening
  • Received plasmapheresis within 12 weeks of screening
  • Pregnant or breastfeeding
  • Body Mass Index (BMI) greater than 45
  • History of cancer, unless in disease free for at least 5 years
  • History of alcoholism or drug/chemical abuse within 12 months prior to screening

Categories Click category to view its trials.
Kidney/Renal Conditions
Participating Locations
Jackson Medical Mall - UMMC Clinics
Pavilion - UMMC
Contact Information
Contact Name: Sherrin Dixon
Phone Number: 601-815-7038
Email: sndixon@umc.edu
Principal Investigator:Shafi, Tariq
How to participate in our Clinical Trials